FIRST_308
01
Informationen
EudraCT Nr.
2023-505660-11-00
Beschreibung
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)
Indikation
Cholangiocarcinoma
02
Kontakt
studienzentrale@kliniken-rt.de 03
